Electrophysiology

CathVision Secures $9 Million in Funding to Accelerate Adoption of ECGenius System & CARDIALYTICS AI-Suite

Retrieved on: 
Tuesday, July 18, 2023

COPENHAGEN, Denmark, July 18, 2023 /PRNewswire/ -- CathVision, a medical technology company developing innovative electrophysiology solutions designed to support clinical decision making in the EP lab, today announced its most recent financing round of $9 million from investors.

Key Points: 
  • The ECGenius System includes a proprietary hardware amplifier capable of acquiring high-fidelity, low-noise cardiac electrograms.
  • The ECGenius System received FDA 510(k) clearance in May 2022 and is currently available.
  • CathVision has achieved several key milestones since the announcement of its last funding round in August 2022, including:
    The ECGenius System is commercially available in the United States.
  • For more information about the ECGenius System, please visit www.cathvision.com/ep-recording-enhanced or email [email protected] .

Stereotaxis and Abbott Combine Technologies in First Integrated Procedures to Treat Arrhythmia Patients

Retrieved on: 
Tuesday, July 18, 2023

The combination of Abbott’s leading cardiac mapping system with Stereotaxis’ advanced robotic technology brings together highly detailed real-time diagnostic information with the unprecedented precision and stability of robotics during therapy delivery.

Key Points: 
  • The combination of Abbott’s leading cardiac mapping system with Stereotaxis’ advanced robotic technology brings together highly detailed real-time diagnostic information with the unprecedented precision and stability of robotics during therapy delivery.
  • The integration of these technologies was announced at Heart Rhythm 2023.
  • “The integration of both systems enables me to address the most complex arrhythmia patients.
  • I am very pleased with this technological advance and the growing recognition that robotics plays an important role for the electrophysiology field.”

Tampa General Hospital Named to Becker's Hospital Review's 2023 List of 'Hospitals and Health Systems with Great Heart Programs'

Retrieved on: 
Monday, July 17, 2023

TAMPA, Fla., July 17, 2023 /PRNewswire/ -- Tampa General Hospital (TGH) has been named one of the top hospitals and health systems in the U.S. delivering exemplary heart and vascular care, according to the 2023 Becker's Hospital Review's "100 Hospitals and Health Systems with Great Heart Programs" list.

Key Points: 
  • TAMPA, Fla., July 17, 2023 /PRNewswire/ -- Tampa General Hospital (TGH) has been named one of the top hospitals and health systems in the U.S. delivering exemplary heart and vascular care, according to the 2023 Becker's Hospital Review's "100 Hospitals and Health Systems with Great Heart Programs" list.
  • Tampa General's inclusion on the list reflects the academic health system's commitment to providing comprehensive, individualized care for patients with a variety of heart and vascular conditions.
  • U.S. News & World Report also ranked Tampa General as "high performing" in Heart Attack and Heart Failure care for 2022-23.
  • Inclusion on the Becker's "100 Hospitals and Health Systems with Great Heart Programs" list is the latest among several high-profile recognitions for Tampa General Hospital, including:

Vistagen Reports New Preclinical Data Supporting Itruvone (PH10) Nasal Spray’s Potential Antidepressant Activity via Peripheral Nasal Neurons without Entry into the Brain

Retrieved on: 
Monday, July 17, 2023

The study demonstrated that a single intranasal administration of radiolabeled itruvone ([14C]PH10) was essentially undetectable in the brain and most other tissues, including blood and plasma.

Key Points: 
  • The study demonstrated that a single intranasal administration of radiolabeled itruvone ([14C]PH10) was essentially undetectable in the brain and most other tissues, including blood and plasma.
  • “Itruvone’s unique mechanism of action is further demonstrated in this new carbon-labeled study,” said Shawn Singh, Chief Executive Officer of Vistagen.
  • This can lead to unwanted side effects and create potential drug-drug interaction concerns for some individuals who require additional medications for other medical conditions.
  • In that study, itruvone was administered intranasally at a daily dose of 3.2 μg and 6.4 μg for 8 weeks.

Metrion Biosciences Expands Senior Leadership Team With Appointments of Dr Robert Kirby as COO and Dr Edward Stevens as CSO

Retrieved on: 
Thursday, July 6, 2023

Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract research and drug discovery company, today announced the appointments of Dr Robert Kirby to Chief Operating Officer and Dr Edward Stevens to Chief Scientific Officer.

Key Points: 
  • Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract research and drug discovery company, today announced the appointments of Dr Robert Kirby to Chief Operating Officer and Dr Edward Stevens to Chief Scientific Officer.
  • This expansion of the senior leadership team will enable Metrion to continue to evolve its ion channel drug discovery service capabilities and ensure the Company delivers ion channel drug discovery services of the highest quality to its customers.
  • Edward obtained his PhD from Imperial College London and completed postdoctoral studies at the University of Cambridge and Parke-Davis UK.
  • Dr Andy Southan, Chief Executive, Metrion Biosciences, said: “I am very pleased to announce these senior management appointments.

NeuroPace Announces CEO Transition

Retrieved on: 
Wednesday, June 28, 2023

MOUNTAIN VIEW, Calif., June 28, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced the appointment of Mr. Joel Becker as NeuroPace President & CEO and member of the Board of Directors effective July 10, 2023. Mr. Michael Favet will be stepping down as CEO and as a member of NeuroPace’s Board of Directors to pursue other opportunities. He has agreed to stay on as a consultant throughout the transition.

Key Points: 
  • Mr. Michael Favet will be stepping down as CEO and as a member of NeuroPace’s Board of Directors to pursue other opportunities.
  • He has agreed to stay on as a consultant throughout the transition.
  • “Joel brings a distinguished track record of successful commercial leadership and is highly qualified to lead NeuroPace as we move into our next phase of commercial expansion and corporate development,” said Frank Fischer, Chairman of the Board of Directors of NeuroPace.
  • “I am thrilled for the opportunity to join NeuroPace at this critical time in the Company’s history,” said Mr. Becker.

Intracardiac Echocardiography Devices Market size to grow by USD 11.5 billion from 2022 to 2030; Increasing number of heart-related medical conditions and treatments to boost the market growth - Facts & Factor

Retrieved on: 
Wednesday, June 28, 2023

Global Intracardiac Echocardiography Devices Market: Growth Drivers

Key Points: 
  • Global Intracardiac Echocardiography Devices Market: Growth Drivers
    Increasing number of heart-related medical conditions and treatments to propel market growth.
  • The global intracardiac echocardiography devices market is projected to grow owing to the increasing number of patients suffering from heart-related conditions and their subsequent treatment.
  • Most traditional tools like transoesophageal echocardiography (TEE) are used to prepare for and act as guiding tools during interventional treatment.
  • Global Intracardiac Echocardiography Devices Market: Segmentation
    The global intracardiac echocardiography devices market is segmented based on end-user, application, and region.

Intracardiac Echocardiography Devices Market size to grow by USD 11.5 billion from 2022 to 2030; Increasing number of heart-related medical conditions and treatments to boost the market growth - Facts & Factor

Retrieved on: 
Wednesday, June 28, 2023

Global Intracardiac Echocardiography Devices Market: Growth Drivers

Key Points: 
  • Global Intracardiac Echocardiography Devices Market: Growth Drivers
    Increasing number of heart-related medical conditions and treatments to propel market growth.
  • The global intracardiac echocardiography devices market is projected to grow owing to the increasing number of patients suffering from heart-related conditions and their subsequent treatment.
  • Most traditional tools like transoesophageal echocardiography (TEE) are used to prepare for and act as guiding tools during interventional treatment.
  • Global Intracardiac Echocardiography Devices Market: Segmentation
    The global intracardiac echocardiography devices market is segmented based on end-user, application, and region.

X-trodes awarded €5.2M Funding from European Innovation Council (EIC) to Advance Breakthrough Home Sleep Monitoring Solution

Retrieved on: 
Tuesday, June 27, 2023

This grant aims to propel the development and commercialization of X-trodes' revolutionary home sleep monitoring solutions.

Key Points: 
  • This grant aims to propel the development and commercialization of X-trodes' revolutionary home sleep monitoring solutions.
  • By leveraging this groundbreaking technology, X-trodes is paving the way for a new era of home sleep monitoring.
  • This breakthrough brings unparalleled convenience and accuracy to sleep monitoring, revolutionizing the field and providing valuable insights for both individuals and healthcare professionals.
  • With this substantial funding, we are well-positioned to expedite the development and commercialization of our groundbreaking home sleep monitoring solutions.

X-trodes awarded €5.2M Funding from European Innovation Council (EIC) to Advance Breakthrough Home Sleep Monitoring Solution

Retrieved on: 
Tuesday, June 27, 2023

This grant aims to propel the development and commercialization of X-trodes' revolutionary home sleep monitoring solutions.

Key Points: 
  • This grant aims to propel the development and commercialization of X-trodes' revolutionary home sleep monitoring solutions.
  • By leveraging this groundbreaking technology, X-trodes is paving the way for a new era of home sleep monitoring.
  • This breakthrough brings unparalleled convenience and accuracy to sleep monitoring, revolutionizing the field and providing valuable insights for both individuals and healthcare professionals.
  • With this substantial funding, we are well-positioned to expedite the development and commercialization of our groundbreaking home sleep monitoring solutions.